文献速递临床试验与 GCP

吉西他滨联合卡培他滨对比吉西他滨单药辅助治疗胰腺癌切除术后患者(ESPAC-4):一项多中心、开放标签、随机、3期试验

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet · 2017-01-25

ESPAC-4研究在6个国家92家医院纳入732例胰腺导管腺癌完全切除术后患者,随机接受吉西他滨联合卡培他滨或吉西他滨单药辅助化疗。联合组中位总生存28.0个月,单药组25.5个月(HR 0.82,95%CI 0.68-0.98,p=0.032)。作者认为联合方案应成为胰腺癌切除术后的新标准治疗。

要点

  • 联合组中位总生存28.0个月,单药组25.5个月(HR 0.82,95%CI 0.68-0.98,p=0.032)。
  • 联合组226/359例报告608起3-4级不良事件,单药组196/366例报告481起。
  • 作者认为吉西他滨联合卡培他滨应成为胰腺导管腺癌切除术后新标准治疗。

核心结论

  • 作者认为吉西他滨联合卡培他滨应成为胰腺导管腺癌切除术后的新标准治疗。

研究设计与样本

  • 3期、两组、开放标签、多中心、随机临床试验,在英格兰、苏格兰、威尔士、德国、法国和瑞典的92家医院开展。
  • 纳入18岁及以上、接受胰腺导管腺癌完全肉眼切除(R0或R1)的患者,术后12周内按1:1随机分组,以国家为分层因素。
  • 联合组接受六个周期吉西他滨1000 mg/m2(每4周中每周一次,共3周)联合口服卡培他滨1660 mg/m2(每周期给药21天、休息7天);单药组接受六个周期吉西他滨单药。
  • 共入组732例患者,730例纳入最终分析:吉西他滨联合卡培他滨组366例,吉西他滨组364例。
  • 主要终点为总生存,在意向治疗人群中分析;毒性在所有接受试验治疗的患者中分析。

主要发现

  • 吉西他滨联合卡培他滨组中位总生存28.0个月(95%CI 23.5-31.5),吉西他滨组25.5个月(95%CI 22.7-27.9),HR 0.82(95%CI 0.68-0.98),p=0.032。
  • 独立数据与安全监察委员会在死亡数达458例(目标480例的95%)时要求报告结果。
  • 吉西他滨联合卡培他滨组359例中226例报告608起3-4级不良事件,吉西他滨组366例中196例报告481起3-4级不良事件。

临床怎么用

  • 作者认为胰腺导管腺癌切除术后应采用吉西他滨联合卡培他滨作为新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. METHODS: We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1:1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m2 gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m2 oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. FINDINGS: Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28·0 months (95% CI 23·5-31·5) compared with 25·5 months (22·7-27·9) in the gemcitabine group (hazard ratio 0·82 [95% CI 0·68-0·98], p=0·032). 608 grade 3-4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse events in 196 of 366 patients in the gemcitabine group. INTERPRETATION: The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma. FUNDING: Cancer Research UK.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017. PMID: 28129987. doi:10.1016/S0140-6736(16)32409-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。